Accenture Prescribes A New Data Management Future For Medtechs
The Last Mile Is The Longest – And The Best
The value of revenue streams derived from new business models is increasingly defined by how well companies manage the data within their ecosystems. Managing the data in the "last mile" subset provides an opportunity for medtech companies to generate income in that revenue stream, says Maximilian Schmid, head of the Global MedTech Practice at Accenture Life Sciences.
You may also be interested in...
From drug delivery by drone to busting the drug rebate model, panelists at CNBC's inaugural health care conference had big visions for the changes Amazon could bring to health care.
Galvani Bioelectronics, the new joint venture between Google’s health-care spinoff Verily and drug giant GSK, will develop a new generation of "bioelectronic medicines" – neuromodulating therapies to treat a wide range of chronic diseases. Brian Otis, CTO of Verily, tells Medtech Insight how the devices that will come out of Galvani differ from existing neuromodulation technologies.
Harvard surgeon Atul Gawande argues that most health care innovations are still “incomplete.” Automation based on data is needed, he says.